Neurogene Inc
NASDAQ:NGNE

Watchlist Manager
Neurogene Inc Logo
Neurogene Inc
NASDAQ:NGNE
Watchlist
Price: 20.28 USD -4.16% Market Closed
Market Cap: 314.1m USD

Relative Value

There is not enough data to reliably calculate the relative value of NGNE.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NGNE Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
10
Median 3Y
0
Median 5Y
0
Industry
7.9
vs History
vs Industry
Median 3Y
-3.5
Median 5Y
-3.6
Industry
24
Forward
-4.5
vs History
vs Industry
Median 3Y
-3.6
Median 5Y
-3.9
Industry
21.6
vs History
vs Industry
Median 3Y
-3.6
Median 5Y
-3.9
Industry
23.7
vs History
44
vs Industry
49
Median 3Y
1
Median 5Y
1.1
Industry
3.4
vs History
vs Industry
13
Median 3Y
0
Median 5Y
0
Industry
8.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.3
vs History
vs Industry
Median 3Y
0.1
Median 5Y
-0.3
Industry
6.7
vs History
vs Industry
Median 3Y
0.1
Median 5Y
-0.3
Industry
7.2
Forward
-0.3
vs History
vs Industry
Median 3Y
0.2
Median 5Y
-0.4
Industry
8.2
vs History
vs Industry
Median 3Y
0.2
Median 5Y
-0.4
Industry
6.7
vs History
42
vs Industry
40
Median 3Y
-0.5
Median 5Y
1.2
Industry
5.7

Multiples Across Competitors

NGNE Competitors Multiples
Neurogene Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Neurogene Inc
NASDAQ:NGNE
299.6m USD 0 -7.4 -0.8 -0.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 079 720.5 -161 975.9 -196 690.4 -194 445.9
US
Abbvie Inc
NYSE:ABBV
399.6B USD 6.7 170.2 16.5 23.4
US
Amgen Inc
NASDAQ:AMGN
177.5B USD 4.9 25.3 18.3 18.3
US
Gilead Sciences Inc
NASDAQ:GILD
150.6B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.7B USD 9.9 31.5 23.1 24.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 067.2 -527.5 -574.4 -559.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
75.6B USD 5.3 16.5 15.7 17.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
60.4B USD 18.8 1 385.9 182.8 221.7
AU
CSL Ltd
ASX:CSL
89.1B AUD 3.8 19.7 13.2 16.5
NL
argenx SE
XBRU:ARGX
47.2B EUR 15.2 35.8 62 63.7
P/S Multiple
Revenue Growth P/S to Growth
US
Neurogene Inc
NASDAQ:NGNE
Average P/S: 3 408 185.8
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
34 079 720.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
2 067.2
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.3
6%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
18.8
46%
0.4
AU
CSL Ltd
ASX:CSL
3.8
5%
0.8
NL
argenx SE
XBRU:ARGX
15.2
49%
0.3
P/E Multiple
Earnings Growth PEG
US
Neurogene Inc
NASDAQ:NGNE
Average P/E: 212.9
Negative Multiple: -7.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 975.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
170.2
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.3
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
9%
1.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 385.9
N/A N/A
AU
CSL Ltd
ASX:CSL
19.7
11%
1.8
NL
argenx SE
XBRU:ARGX
35.8
40%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Neurogene Inc
NASDAQ:NGNE
Average EV/EBITDA: 43
Negative Multiple: -0.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 690.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.3
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.7
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
182.8
N/A N/A
AU
CSL Ltd
ASX:CSL
13.2
8%
1.7
NL
argenx SE
XBRU:ARGX
62
807%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Neurogene Inc
NASDAQ:NGNE
Average EV/EBIT: 49.7
Negative Multiple: -0.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 445.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.3
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.1
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
13%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
221.7
N/A N/A
AU
CSL Ltd
ASX:CSL
16.5
11%
1.5
NL
argenx SE
XBRU:ARGX
63.7
N/A N/A